4D Molecular Therapeutics Goes Neck To Neck With Rival, Shares New Phase 2 Data For Its Wet AMD Candidate
Portfolio Pulse from Vandana Singh
4D Molecular Therapeutics (NASDAQ: FDMT) released interim 24-week data from its Phase 2 PRISM trial for wet AMD, showing promising results in reducing anti-VEGF injections and improving visual outcomes. The company plans to update the Phase 3 trial design in September 2024 and start the first Phase 3 trial in early 2025. Despite the positive data, FDMT shares are down 35.7% to $17.19.
July 17, 2024 | 6:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
4D Molecular Therapeutics released promising Phase 2 data for its wet AMD candidate, showing significant reduction in anti-VEGF injections and improved visual outcomes. Despite the positive data, FDMT shares are down 35.7%.
The positive Phase 2 data indicates strong potential for 4D-150 in treating wet AMD, which could lead to significant market opportunities. However, the current drop in share price suggests market volatility or other underlying concerns. The upcoming Phase 3 trial updates and initiation will be critical for future stock performance.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100